Tuesday February 19, 2019 00:10

MERCK Press Releases

FDA Accepts sBLA and Grants Priority Review for BAVENCIO(R) (avelumab) Plus INLYTA(R) (axitinib) Heathcare—12 Feb 19

Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for BAVENCIO(R) (avelumab) in combination with INLYTA(R) (axitinib)*

Merck to Expand US Biopharmaceutical RD Facility to Advance Innovative Clinical Heathcare—07 Feb 19

Merck to Expand US Biopharmaceutical R&D Facility to Advance Innovative Clinical Pipeline - Merck investing $70 million in U.S. Research & Development Hub - Expansion of R&D footprint to accelerate science and innovation in Oncology,

Merck and GSK Announce Global Alliance to Jointly Develop and Commercialize M7824, a Novel Heathcare—06 Feb 19

- Eight high priority immuno-oncology clinical development studies ongoing or expected to commence in 2019, including studies in non-small cell lung and biliary tract cancers - Merck will receive an upfront payment of EUR300 million and is eligible for

Merck Grants Exclusive License to Vertex for Two DNA Damage Response Heathcare—25 Jan 19

- Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editing applications in six specific genetic disease areas - Merck retains the rights to both compounds in all other disease areas, including oncology -

Merck and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Heathcare—24 Dec 18

Merck and Pfizer Inc. (NYSE: PFE) today announced that data from a planned interim analysis of the Phase III JAVELIN Ovarian 100 study of avelumab* did not support the study's initial hypothesis, and therefore the alliance made the decision to terminate

Merck Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon Heathcare—21 Dec 18

- Agreement enables Merck to maintain an investment in the rapidly advancing oncology field of CAR-T, while focusing its R&D efforts - Intrexon to issue Merck $150 million of Intrexon stock and a $25 million convertible note; Intrexon to receive a

เมอร์ค และ genOway จับมือเป็นพันธมิตรทางธุรกิจ มุ่งสร้างโมเดลหนูทดลองรองรับเทคโนโลยี ไอที—11 Dec 18

- genOway จะได้รับสิทธิแต่เพียงผู้เดียวสำหรับสิทธิบัตรการปรับแต่งจีโนมของเมอร์ค เพื่อผลิตและจำหน่ายโมเดลหนูทดลอง - จะมีการพัฒนาเทคโนโลยีและโซลูชั่นใหม่ ๆ โดยใช้ CRISPR/Cas9 เพื่อเร่งการส่งมอบยาที่มีคุณภาพดียิ่งขึ้นให้กับคนไข้ เมอร์ค (Merck)

Merck and genOway Form CRISPR/Cas9 Strategic Alliance to Develop Rodent IT—11 Dec 18

- genOway to acquire exclusive rights to Merck's foundational genome-editing patents to produce, sell rodent models - New technologies and solutions to be developed using CRISPR/Cas9 to accelerate delivery of better drugs to patients Merck, a leading

Merck Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Heathcare—11 Dec 18

- FDA grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer - First regulatory designation for M7824 following recent presentation of first clinical data in BTC - BTC is a group of rare, aggressive

Merck in Agreement With Cyclica for AI-augmented Screening Platform to Expand Research Heathcare—07 Dec 18

- Agreement to screen discovery and early development compounds using artificial intelligence and computational biophysics - Cloud-based in silico platform that screens small molecules to determine polypharmacological profiles - Evaluation to include

Merck Wins Two RD 100 Awards for Innovation in 2018 IT—28 Nov 18

- BioReliance(R) Viral and Gene Therapy Assay Portfolio wins award in Analytical/Test category - Merck's proxy-CRISPR wins Special Recognition Market Disruptor — Products award Merck, a leading science and technology company, today announced that

เมอร์ค คว้า 2 รางวัลจากเวที RD 100 Awards เชิดชูสุดยอดนวัตกรรมแห่งปี ไอที—28 Nov 18

- นวัตกรรม proxy-CRISPR ของเมอร์ค คว้ารางวัล Special Recognition Market Disruptor — Products เมอร์ค (Merck) บริษัทวิทยาศาสตร์และเทคโนโลยีชั้นนำ ได้ประกาศในวันนี้ว่า ทางบริษัทได้คว้า 2 รางวัลจากเวที R&D 100 Awards ครั้งที่ 56

Merck and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Heathcare—20 Nov 18

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxorubicin (PLD), a type of chemotherapy, compared with PLD did not meet the

Merck Launches BioContinuum(TM) Platform for Next-Generation Process Heathcare—06 Nov 18

- New BioContinuum(TM) Platform provides benefits now, with a mind to continuous process of the future - Expanded Pellicon(R) Single-Pass Tangential Flow Filtration to intensify operations in the purification of therapeutic proteins Merck, the vibrant

เมอร์ค เปิดตัวแพลตฟอร์ม BioContinuum(TM) มุ่งยกระดับศักยภาพกระบวนการผลิต สุขภาพ—06 Nov 18

- แพลตฟอร์มใหม่ BioContinuum(TM) พร้อมมอบประโยชน์แล้ววันนี้ รองรับกระบวนการผลิตแบบต่อเนื่องแห่งอนาคต - แอปพลิเคชันเสริม Pellicon(R) Single-Pass Tangential Flow Filtration ช่วยยกระดับกระบวนการทำโปรตีนเพื่อการรักษาให้บริสุทธิ์ เมอร์ค (Merck)

Merck Presents Updated Results for Bifunctional Immunotherapy M7824 at ESMO 2018 Heathcare—24 Oct 18

- New data presented at the ESMO 2018 Congress include first disclosure of results for M7824 in advanced squamous cell carcinoma of the head and neck, biliary tract cancer and esophageal cancers - Updated data also being presented include non-small cell

เมอร์ค ประกาศข้อตกลงขายธุรกิจโฟลไซโทเมทรี Amnis(R) และ Guava(R) ให้แก่ Luminex ไอที—19 Oct 18

เมอร์ค (Merck) บริษัทวิทยาศาสตร์และเทคโนโลยีที่ไม่หยุดนิ่ง ประกาศลงนามข้อตกลงขั้นสุดท้ายในการขายธุรกิจ Flow Cytometry ให้แก่ Luminex Corporation เป็นมูลค่า 62.5 ล้านยูโร[1] สำหรับการปิดการทำธุรกรรมดังกล่าวจะขึ้นอยู่กับเงื่อนไขตามที่กำหนด

Merck Announces Agreement to Sell Amnis(R) Flow Cytometry and Guava(R) Technologies Businesses to IT—19 Oct 18

- Strategic agreement allows Luminex to increase footprint in multi-billion-dollar flow cytometry market - Deal expected to close at end of 2018 Merck, the vibrant science and technology company, today announced the signing of a definitive agreement to

Merck Inaugurates State-of-the-art Pharma Packaging Center in Darmstadt Heathcare—18 Oct 18

- Expansion of the pharma manufacturing site at Merck's headquarters supports growth of current and future portfolio of pharma medicines - New building dedicated to the packaging and shipping of Merck's pharma medicines in more than 90 countries - EUR63

Global Survey and Documentary Film Expose Emotional Impact of Multiple Heathcare—12 Oct 18

- Merck-sponsored survey developed in collaboration with IACO and Eurocarers reveals lifelong effects of caring for a loved one with MS - #MSInsideOut documentary film, executively produced by Shift.ms, provides artistic take on the experiences of those

Merck Data at ESMO 2018 Congress Highlight Multiple Therapeutics with Potential to Transform Cancer Heathcare—09 Oct 18

Avelumab: LBA6_PR, 659P, 1290P, 1291P, 1282P, 877P; M7824 (TGF β-trap/anti-PD-L1):1048O, 1463P, 1931P, 757P, 643P, 642P, 661P; tepotinib (MET kinase inhibitor): 1377O, 621PD, 698P; M6620: 1437P; M3814: 1845P; M7583: 1014PD; abituzumab: 487P;

Merck Opens M Lab(TM) Collaboration Center in Sao Paulo, Brazil Heathcare—05 Oct 18

- New collaboration center to provide support from pre-clinical through full-scale production in a non-GMP environment - Hands-on customer access to Merck's product portfolio, technical expertise Merck, the vibrant science and technology company, today

เมอร์ค เปิดศูนย์ความร่วมมือลูกค้า M Lab(TM) Collaboration Center ในเซาเปาโล สุขภาพ—05 Oct 18

- ศูนย์ความร่วมมือแห่งใหม่จะให้การสนับสนุนลูกค้าตั้งแต่ขั้นตอนพรีคลินิกไปจนถึงการผลิตเต็มรูปแบบ ในสภาพแวดล้อมแบบ non-GMP - เปิดโอกาสให้ลูกค้าเข้าถึงผลิตภัณฑ์และความเชี่ยวชาญทางเทคนิคของเมอร์คได้โดยตรง เมอร์ค (Merck)

Merck Awarded Australian CRISPR Nickase Patent for Foundational Genome-Editing Heathcare—16 Aug 18

- Patent covers paired Cas9 nickase technology to reduce off-target effects, advance gene therapy and research - Expands company's foundational CRISPR cutting and integration IP necessary to correct genetic defects in gene therapy patients - Merck to

Merck Receives Recommendation for Approval in 21 EU Countries for the New Formulation of Heathcare—26 Jul 18

- German Federal Institute for Drugs and Medical Devices (BfArM) recommends new formulation of Euthyrox(R) for approval in 21 EU countries - BfArM is acting as a representative of all 21 EU countries involved in the EU worksharing procedure Merck, a

Merck Launches Online Platform Fertility.com Heathcare—03 Jul 18

- Offering the latest scientific information to healthcare professionals in the advancing field of fertility - Supporting women, men and couples who are looking for information about fertility and/or undergoing fertility treatment (Photo:

Merck Launches Two New Technologies for Improved Efficiency in Fertility Heathcare—03 Jul 18

- QBOX IVF streamlines data transfer between lab instruments and Electronic Medical Record providers - Geri(R) Assess 2.0 enables automatic detection of key events in embryo and blastocyst development, improving efficiencies in assessment - Merck

Merck Drives Thought Leadership in Ethical Gene Editing IT—13 Jun 18

- Co-authored publication, "Ethical Considerations in the Manufacture, Sale and Distribution of Genome-Editing Technologies," accepted in leading bioethics journal - Highlights importance of science-based bioethics in genome editing and novel processes

Merck Brings Biotechs Closer to Drug Therapy Production and Commercialization IT—06 Jun 18

- Opens North America's first BioReliance(R) End-to-End Biodevelopment Center to help customers with biopharmaceutical manufacturing processes - Accelerates clinical development from DNA to market - "Advance Biotech Grant Program" expands global

Two Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with Heathcare—05 Jun 18

- Two-year follow-up data on meaningful durable response, overall survival (OS) and progression-free survival (PFS) to be presented in patients with metastatic Merkel cell carcinoma (mMCC), a rare and aggressive type of skin cancer Merck and Pfizer